Physician profile
Calvin Baker
NPI 1457814220
$1,592.60
in general payments reported to CMS, 2019-2025
18 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $444 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,550 · Education: $42.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,549.71 |
| Education | $42.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $398.22 | 2024-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $224.79 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $198.77 | 2024-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals Lp | $137.28 | 2024-2025 | Lokelma, Farxiga |
| Travere Therapeutics, INC. | $105.80 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.01 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $64.11 | 2024-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $61.29 | 2024-2025 | Acthar |
| Lilly USA, LLC | $51.29 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $44.40 | 2024-2025 | Ozempic, Wegovy |
| Opko Pharmaceuticals, LLC | $42.89 | 2025 | Rayaldee |
| Ardelyx, INC. | $41.75 | 2024 | Ibsrela |
| Calliditas Therapeutics US INC. | $34.93 | 2024-2025 | Tarpeyo |
| Akebia Therapeutics INC | $22.87 | 2024 | Vafseo |
| Amgen INC. | $21.37 | 2025 | Krystexxa |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $18.63 | 2025 | Empaveli |
| Daiichi Sankyo INC. | $17.57 | 2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.63 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.